Home > Boards > US Listed > Biotechs > Oncolytics Biotech Inc (ONCY)
Followed By 82
Posts 11244
Boards Moderated 0
Alias Born 11/02/2003

Tuesday, February 23, 2021 8:38:57 AM

Re: None

Post# of 210
Seeking Alpha -- Oncolytics surges on encouraging pelareorep + CAR T data in solid tumors

Feb. 23, 2021 7:52 AM ET Oncolytics Biotech Inc. (ONCY)
By: Dulan Lokuwithana, SA News Editor

Oncolytics Biotech (NASDAQ:ONCY) has gained 13.6% in the premarket after announcing preclinical data from a study evaluating the treatment combination of pelareorep and chimeric antigen receptor (“CAR”) T cell in solid tumors.

The data reported with the publication of an electronic poster at the CAR-TCR Summit Europe 2021has indicated that loading CAR T cells with pelareorep significantly improved their persistence and efficacy in a murine solid tumor model (survival rate at end of the study: 57% [4/7]).

The performance of pelareorep, an intravenously delivered immuno-oncolytic virus, contrasts with the preclinical studies using intratumoral infection with the VSV oncolytic virus that weakened CAR T cells, the company said.

A pelareorep boost introduced 8 days later with a single intravenous dose of pelareorep further enhanced the efficacy of pelareorep-loaded CAR T cell (survival rate at end of the study: 100% [7/7]) generating highly persistent CAR T cells, inhibition of recurrent tumor growth, and ultimately tumor cures.

The intravenous boosting with VSV did not augment the efficacy of CAR/Pela therapy or prevent the growth of recurrent tumors (survival rate at end of the study: 42% [3/7]).

"These very exciting data demonstrate pelareorep's ability to overcome major shortcomings of CAR T cells," commented Matt Coffey CEO of Oncolytics.

“This would be a major advancement, as it would substantially broaden the applicability of CAR T cells to a variety of highly prevalent and difficult-to-treat indications."

In October, Oncolytics announced a Phase 1/2 trial to investigate the effect of pelareorep, in combination with Roche's anti-PD-L1 checkpoint inhibitor atezolizumab (Tecentriq), in patients with metastatic pancreatic, colorectal, and advanced anal cancers.
Recent ONCY News

FEATURED SciSparc and Clearmind Medicine Inc. Collaboration Yields Positive Results for its Psychedelic Combination Treatment May 24, 2022 8:36 AM

FEATURED Splash Beverage Group Broadens Reach through Agreement with Maryland's Buck Distributing May 24, 2022 8:12 AM

Ultrack Systems Fully Acquires California Trucking Company M-Loan Inc. MJLB May 24, 2022 9:30 AM

PSYC Teams Up with The Spore Group to Bring Industry-Leading, Psychedelic-Focused Events to Communities Across North America PSYC May 24, 2022 8:30 AM

Electromedical Technologies Announces Financial and Operational Highlights for the Three Months Ended March 31, 2022 EMED May 24, 2022 6:00 AM

HPIL HOLDING (OTC: HPIL) SETTLES ANOTHER LAWSUIT HPIL May 23, 2022 4:30 PM

A.I.S. Resources Identifies Prospective Drill Targets at Reliance Reef and Provides Bright Gold Project Update AIS May 20, 2022 8:00 AM

Lomiko Announces Commencement of Exploration Drilling for its La Loutre Graphite Project LMR May 19, 2022 10:56 AM

PTOP Announces MOBICARD ™ 2.0 Development Contract has been executed PTOP May 19, 2022 10:00 AM

Edison Lithium Spin-Out of Cobalt Assets EDDYF May 19, 2022 8:00 AM

Goldshore Resources Announces Innovative Technology Application for Moss Lake Project Exploration and Closing of Non-Brokered Financing GSHRF May 19, 2022 8:00 AM

Demand Brands kicks off cultivation at Corralitos Farms DMAN May 18, 2022 2:00 PM

Emerging Markets Report: Details, Details SYTA May 18, 2022 11:48 AM

American Green, Inc. ™ (OTC:ERBB) Purchases 40,000sq.ft. Cannabis Grow Building for $3,750,000 ERBB May 18, 2022 9:25 AM

Green Battery Minerals Completes Resource Expansion Drilling at Zone 1 and Intersects Numerous Holes Ranging from 150 - 200 Feet of Graphite CZSVF May 18, 2022 9:19 AM

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y